Illuminating the Hidden Targets of Cancer | Stipple Bio is a biotechnology company harnessing epitope-level precision to create targeted cancer therapies through our proprietary Pointillist Platform, which is designed to identify tumor-specific cell surface epitopes with greater precision. By enabling more selective targeting of cancer cells, the platform aims to improve therapeutic index and unlock targets that have been difficult to address using conventional oncology drug discovery methods. We’re advancing our lead candidate ADC STP-100 as an early application of our epitope-targeting approach.
1
Round
4
Tags
Apr 6, 2026
Latest raise
Funding activity · 1 round
Apr 6, 2026
$100M
Series A
Led by Nextech Invest
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
